Natural history, with clinical, biochemical, and molecular characterization of classical homocystinuria in the Qatari population.
Qatar
classical homocystinuria
consanguinity
founder mutation p.R336C CBS gene
natural history
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
07
10
2018
accepted:
05
04
2019
pubmed:
11
4
2019
medline:
17
9
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
Classical homocystinuria (HCU) is the most common inborn error of metabolism in Qatar, with an incidence of 1:1800, and is caused by the Qatari founder p.R336C mutation in the CBS gene. This study describes the natural history and clinical manifestations of HCU in the Qatari population. A single center study was performed between 2016 and 2017 in 126 Qatari patients, from 82 families. Detailed clinical and biochemical data were collected, and Stanford-Binet intelligence, quality of life and adherence to treatment assessments were conducted prospectively. Patients were assigned to one of three groups, according to the mode of diagnosis: (a) late diagnosis group (LDG), (b) family screening group (FSG), and (c) newborn screening group (NSG). Of the 126 patients, 69 (55%) were in the LDG, 44 (35%) in the NSG, and 13 (10%) in the FSG. The leading factors for diagnosis in the LDG were ocular manifestations (49%), neurological manifestations (45%), thromboembolic events (4%), and hyperactivity and behavioral changes (1%). Both FSG and NSG groups were asymptomatic at time of diagnosis. NSG had significantly higher intelligence quotient, quality of life, and adherence values compared with the LDG. The LDG and FSG had significantly higher methionine levels than the NSG. The LDG also had significantly higher total homocysteine levels than the NSG and FSG. Regression analysis confirmed these results even when adjusting for age at diagnosis, current age, or adherence. These findings increase the understanding of the natural history of HCU and highlight the importance of early diagnosis and treatment. SYNOPSIS: A study in 126 Qatari patients with HCU, including biochemical, clinical, and other key assessments, reveals that patients with a late clinical diagnosis have a poorer outcome, hereby highlighting the importance of early diagnosis and treatment.
Substances chimiques
Cystathionine beta-Synthase
EC 4.2.1.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-830Informations de copyright
© 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect. Science. 1964;143(3613):1443-1445.
Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1-31.
Al-Dewik N, Ali A, Shahbeck N, et al. Natural history, characterization and outcome of classical homocystinuria in the Qatari population. The 13th International Congress of Inborn Errors of Metabolism. R. Giugliani. Rio De Janeiro, Brazil. The Journal of Inborn Errors of Metabolism and Screening. 2017;4:138.
Zschocke J, Kebbewar M, Gan-Schreier H, et al. Molecular neonatal screening for homocystinuria in the Qatari population. Hum Mutat. 2009a;30(6):1021-1022.
El-Said MF, Badii R, Bessisso MS, et al. A common mutation in the CBS gene explains a high incidence of homocystinuria in the Qatari population. Hum Mutat. 2006a;27(7):719.
Magner M, Krupkova L, Honzik T, Zeman J, Hyanek J, Kozich V. Vascular presentation of cystathionine beta-synthase deficiency in adulthood. J Inherit Metab Dis. 2011;34(1):33-37.
Quintas S, Dotor-Garcia Soto J, Alonso-Cerezo MC, Carreras MT. Late diagnosis of homocystinuria in an adult after extensive cerebral venous thrombosis. Pract Neurol. 2018;18(1):49-51.
Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. 2004 Jan 15 [Updated 2017 May 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1524/
Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, et al. Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. J Pediatr. 2010a;156(3):427-432.
Woods E, Dawson C, Senthil L, Geberhiwot T. Cerebral venous thrombosis as the first presentation of classical homocystinuria in an adult patient. BMJ Case Rep. 2017;2017:bcr2016217477.
Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017b;40(1):49-74.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
Tan X, Patel I, Chang J. Review of the Four Item Morisky Medication Adherence Scale (MMAS-4) and Eight Item Morisky Medication Adherence Scale (MMAS-8). University of Minnesota, College of Pharmacy; 2014 Retrieved from the University of Minnesota Digital Conservancy, http://hdl.handle.net/11299/171823.
Al-Dewik NI, Morsi HM, Samara MM, et al. Is adherence to Imatinib Mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol. 2016;10:CMO.S32822.
Södergård B, Halvarsson M, Lindbäck S, Sönnerborg A, Tully MP, Lindblad ÅK. Differences in adherence and motivation to HIV therapy-two independent assessments in 1998 and 2002. Pharm World Sci. 2006;28(4):248-256.
Gramer G, Abdoh G, Ben-Omran T, et al. Newborn screening for remethylation disorders and vitamin B12 deficiency-evaluation of new strategies in cohorts from Qatar and Germany. World J Pediatr. 2017;13(2):136-143.
Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21(7):738-747.
Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2001;24(4):437-447.
El Bashir H, Dekair L, Mahmoud Y, Ben-Omran T. Neurodevelopmental and cognitive outcomes of classical Homocystinuria: experience from Qatar. JIMD Rep. 2015;21:89-95.
Gröbe H. Homocystinuria (cystathionine synthase deficiency). Results of treatment in late-diagnosed patients. Eur J Pediatr. 1980;135(2):199-203.
Adam S, Almeida MF, Carbasius Weber E, et al. Dietary practices in pyridoxine non-responsive homocystinuria: a European survey. Mol Genet Metab. 2013;110(4):454-459.
Schiff M, Blom HJ. Treatment of inherited homocystinurias. Neuropediatrics. 2012;43(6):295-304.
Walter JH, Wraith JE, White FJ, Bridge C, Till J. Strategies for the treatment of cystathionine beta-synthase deficiency: the experience of the Willink biochemical genetics unit over the past 30 years. Eur J Pediatr. 1998;157(Suppl 2):S71-S76.
Garland J, Prasad A, Vardy C, Prasad C. Homocystinuria: challenges in diagnosis and management. Paediatr Child Health. 1999;4(8):557-562.